Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.
Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.
The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.
Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.
The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.
For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.
Castle Biosciences (CSTL) reported financial results for Q2 and the first half of 2021, showcasing a 79% increase in revenue to $22.8 million compared to Q2 2020. The company raised its full-year revenue guidance to $89-93 million, up from $80-83 million, due to a 70% year-over-year growth in DecisionDx®-Melanoma test reports. Notably, the acquisition of myPath® Melanoma lab expanded their diagnostic portfolio. However, operating cash flow declined to $(6.4) million.
Castle Biosciences (Nasdaq: CSTL) announced that its skin cancer gene expression profile tests will be presented at the 2021 AAD Summer Meeting from Aug. 5-8, 2021. Key presentations include:
- Integrating 31-gene expression profiling: Aug. 7, 1:50-2:02 p.m. by Nicholas Taylor, M.D.
- Risk assessment by the 40-gene expression profile test: Aug. 7, 2:32-2:44 p.m. by Aaron Farberg, M.D.
The tests are designed to improve prognostication for melanoma and cutaneous squamous cell carcinoma.
Castle Biosciences, Inc. (Nasdaq: CSTL) presented data on its gene expression profile tests, DecisionDx®-Melanoma and DecisionDx®-SCC, at the DERM2021 conference. DecisionDx-Melanoma predicts metastasis risk using individual tumor data and has shown a 98% negative predictive value in T1-T4 tumors. For DecisionDx-SCC, clinical data emphasizes its reliability (96.3%) and its role in classifying high-risk patients. The studies collectively support enhanced patient management decisions, leveraging genomic information to improve treatment outcomes.
Castle Biosciences (Nasdaq: CSTL) announces continued collaboration with the Melanoma Research Foundation (MRF) to enhance melanoma treatment through research, education, and advocacy. Castle is sponsoring the MRF Miles for Melanoma 5K events across five U.S. cities and the 2021 MRF galas in Chicago, Denver, and New York. MRF has funded over $20.1 million in melanoma research since 1998. Castle's DecisionDx-Melanoma test helps predict melanoma risk, with over 73,396 tests ordered to date, benefiting patient management.
Castle Biosciences (Nasdaq: CSTL) announced that CEO Derek Maetzold will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:30 p.m. ET. The presentation will be available via a live audio webcast on the company’s website, with a replay accessible for two weeks post-event.
Castle Biosciences focuses on dermatologic diagnostics, providing genomic information that informs treatment decisions, particularly for melanoma and other skin cancers. Their innovative tests are designed to aid physicians in making personalized treatment plans.
Castle Biosciences (Nasdaq: CSTL) will release its second quarter financial results on August 9, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET. The company specializes in dermatologic diagnostics, offering genomic tests for melanoma and other skin cancers to support treatment decisions. Castle aims to enhance personalized medicine experiences for patients and physicians. Additionally, the company has ongoing R&D for psoriasis treatment response testing, and it recently acquired the myPath Melanoma laboratory in Salt Lake City.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced a podium presentation on its DecisionDx®-SCC test at the AHNS 10th International Conference from July 22-25, 2021. This 40-gene expression profile test assesses the metastasis risk in high-risk cutaneous squamous cell carcinoma patients. A study involving 278 patients demonstrated significant differences in three-year metastasis-free survival rates based on the DecisionDx-SCC results compared to traditional staging methods. The test enhances risk assessment and informs treatment decisions.
Castle Biosciences (Nasdaq: CSTL) announced data presentations for two gene expression profile tests, DecisionDx-Melanoma and DecisionDx-SCC, at the SDPA Annual Summer Dermatology Conference 2021. DecisionDx-Melanoma predicts melanoma metastasis and recurrence risk, showing that 89% of nurse practitioners view its testing as beneficial to patient care. DecisionDx-SCC assesses metastatic risk in cutaneous squamous cell carcinoma patients, reporting a technical reliability of 96.3% across the first 1000 samples. Both studies underline the clinical utility of these tests in improving treatment decisions.
Castle Biosciences, Inc. (Nasdaq: CSTL) has appointed Kim Caple and Ellen Goldberg to its board of directors, effective immediately. Derek Maetzold, CEO, expressed confidence in their leadership and experience. Caple, currently with Thermo Fisher Scientific, brings expertise in genetic analysis technologies. Goldberg, founder of CHORD Consulting, has a robust background in diagnostics and marketing, notably with the Oncotype DX Breast Cancer Assay. The company specializes in dermatologic diagnostics, providing genomic information for better treatment decisions.
Castle Biosciences, Inc. (Nasdaq: CSTL) has been recognized in the Houston Chronicle’s CHRON 100 list for the second consecutive year, highlighting its success in Market Value, Market Return, and Revenue Growth. The recognition reflects Castle's ongoing growth in genomic diagnostics for dermatologic conditions, primarily through its flagship product, the DecisionDx®-Melanoma. The firm plans to enhance its diagnostic suite further, contributing to its stature as a leader in the sector and aiming to improve patient outcomes.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
What does Castle Biosciences specialize in?
When was Castle Biosciences founded?
What types of cancer does Castle Biosciences have tests for?
What are some of Castle Biosciences' notable products?
Is Castle Biosciences involved in research for new diagnostic tests?
Where can I find more information about Castle Biosciences and its products?
What is the primary mission of Castle Biosciences?
Does Castle Biosciences collaborate with other entities?
What is Castle Biosciences' financial condition?
How does Castle Biosciences contribute to cancer care?
